LT3226B - Composition for stabilizing blood plasma during pasteurisation and pasteurized plasma solution for therapeutic use - Google Patents
Composition for stabilizing blood plasma during pasteurisation and pasteurized plasma solution for therapeutic use Download PDFInfo
- Publication number
- LT3226B LT3226B LTIP338A LTIP338A LT3226B LT 3226 B LT3226 B LT 3226B LT IP338 A LTIP338 A LT IP338A LT IP338 A LTIP338 A LT IP338A LT 3226 B LT3226 B LT 3226B
- Authority
- LT
- Lithuania
- Prior art keywords
- plasma
- composition
- pasteurized
- composition according
- therapeutic use
- Prior art date
Links
- 210000002381 plasma Anatomy 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000009928 pasteurization Methods 0.000 title claims abstract description 19
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 11
- 230000000087 stabilizing effect Effects 0.000 title claims description 8
- 238000000034 method Methods 0.000 claims abstract description 13
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 12
- 239000000600 sorbitol Substances 0.000 claims description 12
- 239000004472 Lysine Substances 0.000 claims description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 11
- 239000001509 sodium citrate Substances 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 10
- 239000004227 calcium gluconate Substances 0.000 claims description 10
- 229960004494 calcium gluconate Drugs 0.000 claims description 10
- 235000013927 calcium gluconate Nutrition 0.000 claims description 10
- 229940038773 trisodium citrate Drugs 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 9
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 229960002668 sodium chloride Drugs 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 108010091326 Cryoglobulins Proteins 0.000 abstract description 3
- 230000003019 stabilising effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960000182 blood factors Drugs 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- 241001480512 Mammalian orthoreovirus 3 Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000282 fibrinogen degradation product Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9201604A FR2687317B1 (fr) | 1992-02-13 | 1992-02-13 | Composition pour stabiliser le plasma sanguin en cour de pasteurisation et solution plasmatique pasteurisee a usage therapeutique. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTIP338A LTIP338A (en) | 1994-08-25 |
| LT3226B true LT3226B (en) | 1995-04-25 |
Family
ID=9426597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTIP338A LT3226B (en) | 1992-02-13 | 1993-02-12 | Composition for stabilizing blood plasma during pasteurisation and pasteurized plasma solution for therapeutic use |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0556096B1 (pl) |
| JP (2) | JP4010573B2 (pl) |
| AT (1) | ATE171074T1 (pl) |
| BR (1) | BR9300524A (pl) |
| CA (1) | CA2089446C (pl) |
| CZ (1) | CZ285573B6 (pl) |
| DE (1) | DE69321007T2 (pl) |
| DK (1) | DK0556096T3 (pl) |
| EE (1) | EE03091B1 (pl) |
| ES (1) | ES2121065T3 (pl) |
| FI (1) | FI103380B (pl) |
| FR (1) | FR2687317B1 (pl) |
| HU (1) | HU210026B (pl) |
| LT (1) | LT3226B (pl) |
| LV (1) | LV10195B (pl) |
| NO (1) | NO306532B1 (pl) |
| PL (1) | PL174098B1 (pl) |
| RU (1) | RU2112522C1 (pl) |
| SK (1) | SK280665B6 (pl) |
| UA (1) | UA27102C2 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9501189D0 (sv) * | 1995-03-31 | 1995-03-31 | Pharmacia Ab | Protein formulation |
| US5616159A (en) * | 1995-04-14 | 1997-04-01 | Corning Incorporated | Method of forming high purity fused silica having high resistance to optical damage |
| US6619073B2 (en) | 1996-03-05 | 2003-09-16 | Corning Incorporated | Method of increasing the initial transmittance of optical glass |
| US6361933B1 (en) | 1996-06-14 | 2002-03-26 | Biostore New Zealand Limited | Solutions for the preservation of tissues |
| US5962213A (en) * | 1996-06-14 | 1999-10-05 | Biostore New Zealand Limited | Compositions and methods for the preservation of living tissues |
| US6114107A (en) * | 1996-06-14 | 2000-09-05 | Biostore New Zealand Limited | Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues |
| US6037116A (en) * | 1996-06-14 | 2000-03-14 | Biostore New Zealand, Ltd. | Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials |
| AU725247B2 (en) * | 1996-06-14 | 2000-10-12 | Biostore New Zealand Limited | Compositions and methods for the preservation of living tissues |
| US5827640A (en) * | 1996-06-14 | 1998-10-27 | Biostore New Zealand Limited | Methods for the preservation of cells and tissues using trimethylamine oxide or betaine with raffinose or trehalose |
| US5879875A (en) * | 1996-06-14 | 1999-03-09 | Biostore New Zealand | Compositions and methods for the preservation of living tissues |
| RU2174841C1 (ru) * | 2000-06-06 | 2001-10-20 | Российский научно-исследовательский институт гематологии и трансфузиологии | Способ получения пула нормальной плазмы |
| US6915665B2 (en) | 2000-10-31 | 2005-07-12 | Corning Incorporated | Method of inducing transmission in optical lithography preforms |
| US20060019234A1 (en) * | 2004-07-22 | 2006-01-26 | Shanbrom Technologies, Llc | Modern blood banking employing improved cell preservation composition |
| ES2264403B1 (es) * | 2006-06-22 | 2007-11-01 | Grifols S.A. | Medio de suspension de hematies. |
| DE102011056142A1 (de) * | 2011-12-07 | 2013-06-13 | Manfred Rüdinger | Metabolisierbare Salze und deren Verwendung in Diagnostik und Therapie |
| RU2639446C1 (ru) * | 2016-11-23 | 2017-12-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ хранения плазмы крови, содержащей лекарственные вещества с нестабильными фенольными гидроксилами |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2664165A1 (fr) | 1990-07-03 | 1992-01-10 | Lille Transfusion Sanguine | Composition pour stabiliser le plasma sanguin en cours de pasteurisation. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3045153A1 (de) * | 1980-11-29 | 1982-07-08 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x |
| DE3230849A1 (de) * | 1982-08-19 | 1984-02-23 | Behringwerke Ag, 3550 Marburg | Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung |
| DE3237512A1 (de) * | 1982-10-09 | 1984-04-12 | Behringwerke Ag, 3550 Marburg | Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat |
| US4470968A (en) * | 1983-01-13 | 1984-09-11 | Miles Laboratories, Inc. | Pasteurized therapeutically active blood coagulation factor concentrates |
| JPS59134730A (ja) * | 1983-01-20 | 1984-08-02 | Green Cross Corp:The | 血液凝固第８因子の加熱処理法 |
| DE3330770A1 (de) * | 1983-08-26 | 1985-03-14 | Behringwerke Ag, 3550 Marburg | Verfahren zur pasteurisierung von humanplasma |
| FR2650508A1 (fr) * | 1989-08-01 | 1991-02-08 | Fondation Nale Transfusion San | Colle pasteurisee pour reunir des tissus humain ou animal |
-
1992
- 1992-02-13 FR FR9201604A patent/FR2687317B1/fr not_active Expired - Fee Related
-
1993
- 1993-02-04 DK DK93400279T patent/DK0556096T3/da active
- 1993-02-04 DE DE69321007T patent/DE69321007T2/de not_active Expired - Lifetime
- 1993-02-04 EP EP93400279A patent/EP0556096B1/fr not_active Expired - Lifetime
- 1993-02-04 ES ES93400279T patent/ES2121065T3/es not_active Expired - Lifetime
- 1993-02-04 AT AT93400279T patent/ATE171074T1/de not_active IP Right Cessation
- 1993-02-09 CZ CZ93161A patent/CZ285573B6/cs not_active IP Right Cessation
- 1993-02-09 BR BR9300524A patent/BR9300524A/pt not_active Application Discontinuation
- 1993-02-10 SK SK82-93A patent/SK280665B6/sk not_active IP Right Cessation
- 1993-02-10 LV LVP-93-113A patent/LV10195B/en unknown
- 1993-02-11 NO NO930473A patent/NO306532B1/no not_active IP Right Cessation
- 1993-02-11 PL PL93297699A patent/PL174098B1/pl not_active IP Right Cessation
- 1993-02-12 HU HU9300377A patent/HU210026B/hu not_active IP Right Cessation
- 1993-02-12 FI FI930630A patent/FI103380B/fi not_active IP Right Cessation
- 1993-02-12 LT LTIP338A patent/LT3226B/lt not_active IP Right Cessation
- 1993-02-12 CA CA002089446A patent/CA2089446C/fr not_active Expired - Fee Related
- 1993-02-12 JP JP04609393A patent/JP4010573B2/ja not_active Expired - Fee Related
- 1993-06-15 UA UA93002940A patent/UA27102C2/uk unknown
-
1994
- 1994-05-23 EE EE9400005A patent/EE03091B1/xx not_active IP Right Cessation
-
1998
- 1998-02-12 RU RU93004727A patent/RU2112522C1/ru not_active IP Right Cessation
-
2006
- 2006-08-02 JP JP2006211141A patent/JP4472672B2/ja not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2664165A1 (fr) | 1990-07-03 | 1992-01-10 | Lille Transfusion Sanguine | Composition pour stabiliser le plasma sanguin en cours de pasteurisation. |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3400413C2 (pl) | ||
| LT3226B (en) | Composition for stabilizing blood plasma during pasteurisation and pasteurized plasma solution for therapeutic use | |
| US4623717A (en) | Pasteurized therapeutically active protein compositions | |
| DK156698B (da) | Fremgangsmaade til pasteurisering af et materiale indeholdende et termisk foelsomt, terapeutisk aktivtprotein valgt blandt alfa-l-antitrypsin, antithrombin-iii, praekallikrein, antihaemofil faktor (faktorviii) og fibronectin | |
| JP3133338B2 (ja) | ウイルス的に安全な生物学的組成物の調製方法 | |
| US4379085A (en) | Heat stabilization of plasma proteins | |
| ES2382934T3 (es) | Procedimiento de estabilización de un crioprecipitado de proteinas plasmáticas destinado a someterse a un tratamiento térmico de inactivación viral | |
| MXPA05011283A (es) | Composicion de trombina estable. | |
| HU218490B (hu) | Eljárás vírus inaktiválására poliéter és kaotróp szer jelenlétében | |
| EP0292003B1 (en) | Stabilzation of biological and pharmaceutical products during inactivation of viral and bacterial contaminants | |
| FI96918B (fi) | Koostumus veriplasman stabiloimiseksi pastöroinnin aikana | |
| JPS6140392B2 (pl) | ||
| JPS58198292A (ja) | ヒト胎盤性ロイシンアミノペプチダ−ゼの加熱安定化法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20110212 |